Recombinant VEGFA antibody

Catalog No. ABIN7540554

Supplier Product No.: 400-001-mt5

The Humanized Monoclonal anti-VEGFA antibody is suitable to detect VEGFA in samples from Human. It has been validated for WB, ELISA and FACS.

Quick Overview for Recombinant VEGFA antibody (ABIN7540554)

Target: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Antibody Type: Recombinant Antibody

Fragment: scFv fragment

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This VEGFA antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Clone: Abz5

Product Details anti-VEGFA Antibody

Supplier Product No.: 400-001-mt5

Supplier: Rockland

Purpose: Recombinant Anti-VEGF RTH258 scFv Antibody

Purification: Humanized Recombinant anti-VEGFA ScFV fragment was expressed in CHO cells.

Purity: > 95 % by SDS-PAGE analysis

Sterility: Sterile filtered

Isotype: IgG1

Application Details

Application Notes:

ELISA_Dilution: User Optimized

Flow_Cytometry_Dilution: User Optimized

Western_Blot_Dilution: User Optimized

Comment:

Humanized Recombinant Anti-VEGFA ScFV fragment Antibody has been tested for use in Flow Cytometry, Western Blot, and ELISA. This antibody recognizes structured VEGF-A and will work in western blot when the protein has not been denatured with DTT or bMe. Although not tested, this antibody could be useful in in IHC and in in-vivo and other cellular assays. Specific conditions for reactivity should be optimized by the end user

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer:

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Stabilizer: 30 % Glycerol

Preservative: None

Preservative: Without preservative

Storage: 4 °C

Storage Comment: Store vial at 2-8° C. Dilute only prior to immediate use.

Expiry Date: 6 months

Target Details for VEGFA

Target: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Alternative Name: VEGF-A

Background: Anti-VEGF-A Antibody, RTH258, Brolucizumab, Vascular endothelial growth factor A, VEGF A, VEGFA, Vascular permeability factor, VPF,VEGF is a potent mitogen in embryonic and somatic angiogenesis with specificity for vascular endothelial cells. VEGF forms homodimers and exists in four different isoforms. Overall, the VEGF monomer resembles that of PDGF, but its N-terminal segment is helical rather than extended. VEGF shares homologies of about 21 % and 24 % respectively with the A and B chains of human platelet-derived growth factor (PDGF), and has complete conservation of the eight cysteine residues found in both mature PDGF chains. The cysteine knot motif is a common feature of this domain. The homology is not reflected in function, however, since the cell types responsive to VEGF are distinct from those responsive to homo- and heterodimers of the PDGF chains. This protein is a glycosylated mitogen that acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. VEGF-A also has been shown to have effects on a number of other cell types (e.g. stimulation of monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells). VEGF-A is also a vasodilator, it increases microvascular permeability, and was originally referred to as vascular permeability factor. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Antibody against VEGF-A (Bevacizumab or brand name Avastin) is approved for treatment of cancer by inhibiting angiogenesis. Ranibizumab, a Fab fragment of Avastin or so-called Lucentis is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. This antibody has its amino acid sequence like one of Brolucizumab (sold under trade names Beovu or Vsiqq) - a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Gene ID: 7422

NCBI Accession: NP_001020537

UniProt: P15692

Pathways: RTK Signaling, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling